The G-protein coupled receptors for 9 -tetrahydrocannabinol, the major psychoactive principle of marijuana, are known as cannabinoid receptors of type 1 (CB1) and 2 (CB2) and play important functions in degenerative and inflammatory disorders of the central nervous system. Whilst CB1 receptors are mostly expressed in neurons, where they regulate neurotransmitter release and synaptic strength, CB2 receptors are found mostly in glial cells and microglia, which become activated and over-express these receptors during disorders such as Alzheimer's disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinson's disease, and Huntington's chorea. The neuromodulatory actions at CB1 receptors by endogenous agonists ('endocannabinoids'), of which anandamide and 2-arachidonoylglycerol are the two most studied representatives, allows them to counteract the neurochemical unbalances arising during these disorders. In contrast, the immunomodulatory effects of these lipophilic mediators at CB2 receptors regulate the activity and function of glia and microglia. Indeed, the level of expression of CB1 and CB2 receptors or of enzymes controlling endocannabinoid levels, and hence the concentrations of endocannabinoids, undergo time-and brain region-specific changes during neurodegenerative and neuroinflammatory disorders, with the initial attempt to counteract excitotoxicity and inflammation. Here we discuss this plasticity of the endocannabinoid system during the aforementioned central nervous system disorders, as well as its dysregulation, both of which have opened the way to the use of either direct and indirect activators or blockers of CB1 and CB2 receptors for the treatment of the symptoms or progression of these diseases.
In 1993 another receptor for THC was cloned by homology with CB 1 , found to be highly expressed in immune cells and tissues and nearly absent in the brain, and named cannabinoid receptor of type 2 (CB 2 ). Like CB 1 , CB 2 is coupled to G i/o proteins and AC inhibition and mitogen-activated protein kinase stimulation, but not to VACC inhibition. It has also been suggested to be coupled to sphingomyelinase activation and ceramide formation, although it does not seem to share with CB 1 the capability to couple with G s or G q/11 [2] . Some central nervous system (CNS) neurons do express low levels of CB 2 [6, 7] , but under several pathological, namely neuroinflammatory, conditions this receptor is strongly upregulated particularly in glia and microglia [8] .
Clearly, cannabinoid receptors have resisted evolution not because they can be activated by THC, but in order to convey important physiological messages. In order to do so, they require endogenous ligands. These "endocannabinoids" [9] were first identified in the 1990's, and the most studied of them to this date are N-arachidonoylethanolamine (anandamide) [10] and 2-arachidonoylglycerol (2-AG) [11, 12] . Enzymes for the biosynthesis and inactivation of these two metabolites have been identified and in most cases cloned [13] . Of these, fatty acid amide hydrolase (FAAH, responsible for anandamide and, under certain conditions, 2-AG enzymatic hydrolysis) [14] and monoacylglycerol lipase (MAGL) (specific for 2-AG hydrolysis) [15] , and diacylglycerol lipases (DAGL) and (catalyzing 2-AG biosynthesis from sn-2-arachidonate containing diacylglycerols) [16] have been particularly studied, also in terms of the development of selective inhibitors [13, 17] . Several enzymes appear to contribute to anandamide production from its phospholipid precursor, N-arachidonoyl-phosphatidylethanolamine [18] , and the task of selectively inhibiting the biosynthesis of this endocannabinoid, therefore, appears more difficult at the moment. Interestingly, in the CNS, CB 1 and metabolic enzymes for 2-AG, but not anandamide, are anatomically distributed in a way to allow to the former compound to play a role as "retrograde" inhibitor of both excitatory and inhibitory neurotransmitter release. CB 1 and MAGL are often localized in pre-synaptic boutons and the biosynthetic enzymes in the proximity of the dendritic spine and of metabotropic receptors (such as group I metabotropic glutamate receptors), the activation of which was suggested to modulate the strength of synaptic plasticity via endocannabinoid formation [19] . Thus, 2-AG synthesized post-synaptically by DAGL , acts retrogradely on pre-synaptic CB 1 to inhibit, usually via inhibition of VACC, the release of either glutamate or GABA, in a mechanism that might involve one single synapse or two adjacent synapses, and regulate both short-and long-term forms of synaptic plasticity. More importantly, if 2-AG is produced following strong depolarization of the post-synaptic neuron, for example, by excessive glutamate release from the pre-synaptic terminal its inhibition of pre-synaptic glutamate release might function as a "circuit breaker" in those acute or chronic neurological conditions in which glutamate excitotoxicity plays a major role [20] . Possibly by acting instead in an autocrine manner, endocannabinoids might also stimulate adult neurogenesis and oligodendrocyte formation via CB 1 [21] . The latter phenomenon could explain some other neuroprotective effects of this important modulatory system. By acting at CB 2 , endocannabinoids can instead regulate the reactivity of glial and microglial cells, which usually over-express this receptor during neuroinflammatory disorders. The CB 2 -mediated effects on these cells are very complex and include both stimulation of cell migration and inhibition of the release of several types of pro-inflammatory cytokines [8] . It can be hypothesized that CB 2 activation, depending on its timing and exact localization, might first play a protective action when the inflammatory response is beneficial, by helping to recruit glial cells and microglia to the site of neuronal damage. In more advanced phases of these neurodegenerative disorders, when the self-sustained inflammatory response causes leakage of the blood-brain barrier and entry of macrophages and T-lymphocytes, CB 2 activation would reduce inflammation via inhibition of interleukin-6 and tumor necrosis factor-(TNF-). These protective actions, however, might become dysregulated, thus explaining why also CB 2 antagonists have produced some therapeutic benefit in neuroinflammatory disorders such as experimental allergic encephalomyelitis [22] .
Endocannabinoids, and anandamide in particular, are known to interact also with non-CB 1 , non-CB 2 targets, the most studied of which is the transient receptor potential vanilloid type 1 (TRPV1) channel, which is activated by anandamide at low micromolar or sub-micromolar concentrations [23, 24] . TRPV1 is expressed in the CNS [25] , where it can enhance glutamatergic signalling and exacerbate excitotoxicity [26, 27] . It can also modulate motor activity at the level of the basal ganglia, and such action might become important under conditions of impaired locomotor control, such as during some neurodegenerative disorders (see below). Therefore, the impact on these disorders of drugs that act by enhancing anandamide levels, such as FAAH inhibitors, which can theoretically enhance indirectly both cannabinoid receptor and TRPV1 channel activity, should always be carefully evaluated.
Based on this background, it is easy to postulate that the endocannabinoid signaling system will play an important role in neurodegenerative/neuroinflammatory disorders. Here we discuss the evidence in favor of this premise, focusing mostly on those effects of endocannabinoids, synthetic cannabimimetic compounds or THC that are mediated by CB 1 and CB 2 .
ALZHEIMER'S DISEASE AND AMYLOID--INDUCED NEUROTOXICITY AND MEMORY IMPAIREMENT
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder, characterized by a progressive loss of cognitive abilities and, eventually, dementia. Although in most cases the etiology of the disease is unknown, the neuropathology of different types of AD is characterized by the presence of senile neuritic plaques, extracellular insoluble aggregates of -amyloid (A ), neurofibrillary tangles, and intraneuronal accumulation of hyper-phosphorylated protein tau. Studies aimed at understanding the possible cannabinoid receptor-mediated inhibition of Ainduced neurotoxicity, gliosis, neuroinflammation, and memory deficits have been performed both in vitro and in vivo. Endocannabinoids inhibited A toxicity via a CB 1 -mediated mechanism and activation of the mitogen activated protein kinase pathway in neuronal cell lines [28] . The selective CB 2 agonist, JWH-015, reduced secretion of the pro-inflammatory molecules, TNF-and nitric oxide, induced either by interferon-or A , and also attenuated the CD40-mediated inhibition of microglial phagocytosis of the A 1-42 peptide [29] . Moreover, stimulation of CB 1 or blockade of CB 2 attenuated A -induced C6 glioma cell line proliferation and over-expression of glial fibrillary acidic protein and S100 protein (a marker of gliosis) [30] . On the other hand, A down-regulated CB 1 and up-regulated CB 2 . In addition, the CB 1 /CB 2 agonist WIN-55, 212-2 counteracted both A -mediated activation of microglia in culture and A toxic effects in vivo, and prevented the cognitive deficits in the spatial navigation task in Apeptide-treated rats [31] .
Other experimental data suggest an involvement of cannabinoid receptors in cognitive processes and A -induced amnesia. In particular the participation of CB 1 in amnesia induced by A 1-42 was tested in mice in a step-through passive avoidance paradigm. The selective CB 1 antagonist, SR141716A (rimonabant), which per se did not cause any significant change in the capacity of control mice to retain passive avoidance response, was able to revert the amnesic effect induced by the A fragment injected 7 days prior to the learning trial, if administered 30 min before the retention test [32] . In the same model of A -induced neurotoxicity, in rats, a transient elevation of 2-AG and CB 2 levels, accompanied by upregulation of DAGL , was observed in the hippocampus of treated rats 12 days after A peptide injection, whereas at a later stage (20 days) anandamide levels were reduced [33] . In addition, pharmacological enhancement of endocannabinoid levels through the sub-chronic administration of an endocannabinoid reuptake inhibitor, VDM-11, 3-days after injection of the A peptide, reversed apoptosis and gliosis in hippocampal neurons, whereas administration was ineffective when done 7-days after the A peptide. When these experiments were repeated in mice using exactly the same treatment protocols, VDM-11, given 3-days after A peptide injection, ameliorated memory impairment in the passive avoidance test, but worsened it when administered 7 days after peptide administration [33] . Double transgenic TASTPM mice, which overexpress the amyloid precursor protein and presenilin-1 genes, were used to investigate the involvement of cannabinoid receptors in the amelioration of cognitive processes in the familial form of AD, induced by novel environmental conditions [34] . Five weeks of novel cage stress applied in adulthood to mice delayed the onset of short-term contextual memory deficit, and attenuated soluble and insoluble amyloid accumulation in the hippocampus and frontal cortex, but did not affect the age-related increase of endocannabinoid levels [34] . The involvement of cannabinoid receptors in the A removal process has also been investigated [35] . Activation of CB 2 by the selective agonist JWH-015 induced Aplaque removal from human AD frozen hippocampal and parahippocampal cortex. Moreover, JWH-015-induced phagocytosis of A deposits, which was reverted by pre-treatment with the selective antagonist SR144528, seemed to be cell-specific, as the human macrophage THP-1 cell line, but not U373MG astrocytoma cells, responded to agonist treatment [35] .
The potential of endocannabinoids as possible diagnostic biomarkers for AD was also evaluated [36] . However, no significant differences in endocannabinoid concentrations in plasma samples from patients with AD compared with healthy controls were found, although an inverse correlation between plasma levels of 2-AG, but not anandamide, and TNF-was observed [36] . Up-regulation of both CB 2 and FAAH in glial cells associated with senile plaques [37] or in patients with Down's syndrome (which is considered a human model of AD since, by the age of 40, virtually all patients with this syndrome have sufficient A plaques for AD diagnosis) [38] had been instead previously reported, whereas no changes [39] or a even a reduction [31] of CB 1 in AD brain were described.
MULTIPLE SCLEROSIS
Multiple sclerosis (MS), or encephalomyelitis disseminate, is a chronic, immune-mediated CNS disorder characterized by demyelinating lesions in the brain and spinal cord. MS patients can be affected by a relapsing-remitting form of the disease, but a large proportion of patients will progress to a secondary progressive form of the disease, which results in a gradual and progressive loss of neurological function. In the past few years, several lines of evidence supported the beneficial effects of cannabinoids in different animal models of MS: EAE (experimental autoimmune encephalomyelitis), CREAE (chronic relapsing experimental allergic encephalomyelitis) and TMEV-IDD (Theiler murine encephalomyelitis virus-induced demyelinating disease).
EAE
EAE rodent models of MS are obtained following immunization of animals with myelin-associated antigens. Initiation and maintenance of EAE is largely mediated by T lymphocytes, which infiltrate the CNS and cause a cell-mediated immune response, progression of inflammation and demyelinization [40, 41] . The induction of EAE in Lewis rats was associated with changes in CB 1 in striatal and cortical neurons [42] . In particular, a decrease of CB 1 mRNA levels and activation of GTP-binding proteins was observed in the caudate-putamen but not in hippocampus, limbic structures, and cerebellum. In addition, CB 1 binding, but not mRNA levels, was also decreased in the cerebral cortex. Interestingly, changes of CB 1 , found in the basal ganglia of EAE rats, disappear after treatment with rolipram, an inhibitor of type IV phosphodiesterase, which is able to suppress EAE in different species. Endocannabinoid levels are also found decreased in motor related regions of EAE rats, and inhibitors of endocannabinoid cellular reuptake reduced the magnitude of the neurological impairment [43] . In another study, however, the cell damage induced by EAE did not alter endocannabinoid levels, and the authors suggested that the high brain levels of interferonassociated with EAE might disrupt endocannabinoid-mediated neuroprotection by interfering with purinergic P 2x7 -induced stimulation of 2-AG biosynthesis [44] . Increased levels of anandamide were instead detected in the brains of EAE mice in the acute phase of the disease with concomitant up-regulation of Nacylphosphatidylethanolamine-specific phospholipase D and downregulation of FAAH activity. However, cannabinoid CB 1 receptor binding was reduced in the striatum and unchanged in the cortex of these mice [45] .
There is some controversy about the cellular players involved in the regulation of pathogenic mechanisms by the endocannabinoid system in MS and experimental models. In particular, some authors reported that CB 1 expression by neurons, but not T cells, is required for cannabinoid-mediated EAE suppression, whereas CB 2 expression by encephalitogenic T cells is instead critical for controlling inflammation associated with EAE [46] . Other authors instead suggested that cannabinoid-induced immunosuppression is associated with a reduction of T cell responsiveness and accumulation of inflammatory cells via CB 1 activation, whereas no immunosuppressive effect via CB 2 in C57BL/6 or ABH mice was detected [47] . In another study, CB 2 was shown to be involved in the trafficking of myeloid progenitors towards the inflamed spinal cord since an increased number of CD34 + cells, a marker for primitive myeloid progenitors, was evident in the spinal cord of CB 2 -deficient mice that developed a notably higher symptomatic EAE score. In addition, an increased axonal loss, together with extended microglial-cell (CD11b + ) activation and T-lymphocyte (CD4 + ) infiltration, was observed in CB 2 -deficient mice [48] .
CREAE
In the CREAE mouse model of MS, a particular strain of mice, the ABH Biozzi mice, are injected subcutaneously in the flank with mouse spinal cord homogenate in complete Freund's adjuvant containing Mycobacterium tuberculosis H37Ra and Mycobacterium butyricum. After an incubation phase, attacks of paralysis alternate with remission periods, and an acute phase can be distinguished from a chronic, late phase. In this latter phase, spasticity is observed during remission, normally after 3-4 paralysis episodes. Using this model it was suggested that the endocannabinoid system may be tonically active in MS [49] , as exogenous antagonists of CB 1 worsened both tremor and spasticity in CREAE, whereas agonists ameliorated these signs. Both anandamide and 2-AG levels were enhanced during the spastic phase in the spinal cord and brain of CREAE mice and their levels returned to basal at relapse, when mouse hind limbs are no longer spastic and paralysis occurs [50] . CREAE animals were analyzed at different phases of disease progression (acute, remission and chronic) to examine mRNA expression of CB 1 . A moderate decrease in CB 1 density in the caudate-putamen during the acute phase of CREAE, that disappeared during the remission phase and reappeared in the chronic phase, was observed. The same pattern of CB 1 plasticity was found in the cerebellum, while the initial reduction in the density of CB 1 in the globus pallidus was maintained during later phases [51] . In agreement with a protective role of endocannabinoids in CREAE mice, genetic inactivation of CB 1 caused a more severe clinical manifestation of the disorder [52] , whereas inhibitors of endocannabinoid cellular reuptake and enzymatic hydrolysis ameliorated neuronal cell damage and spasticity [53] [54] [55] .
TMEV-IDD
Theiler's murine encephalomyelitis virus is a common enteric mouse picoronavirus, but when injected into the CNS of susceptible mouse strains induces a demyelinating disease (i.e. TMEV-IDD) that serves as a model for human MS. Intraperitoneal injection of WIN55, 212-2, arachidonoylchloroanandamide or JWH-015, i.e. CB 1 /CB 2 , CB 1 and CB 2 agonists, respectively, in mice with established TMEV-IDD improved motor function by modulating microglia and lymphocyte infiltration into the spinal cord [56] . Furthermore, WIN55, 212-2 ameliorated progression of clinical disease symptoms and down-regulated both virus and myelin epitope-specific Th1 effector functions whilst inhibiting TNF-, interleukin-1 , and interleukin-6 expression [57] . In this MS model, OMDM-1 and UCM707, two inhibitors of cellular anandamide reuptake, improved motor function in infected mice and reduced neuroinflammation by enhancing endocannabinoid levels. Additionally, these inhibitors decreased the production of proinflammatory mediators such as nitric oxide. TNF-, interleukin-1 , and interleukin-6 [58, 59] . Finally, enhancement of the endocannabinoid tone, obtained through treatment with UCM707, led to neuroprotection against -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid -induced excitotoxicity and afforded therapeutic benefit [60] .
Recently, the effect of WIN55, 212-2 was investigated in this MS model also on the regulation of adhesion molecules, such as intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 [61, 62] , which are implicated in the pathogenesis of MS [63] . In particular the administration of WIN55, 212-2, at the time of virus infection suppressed both intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in brain endothelium, together with a reduction in perivascular CD4+ T lymphocytes infiltrates and microglial responses [63] .
DATA FROM HUMAN SUBJECTS WITH MS
Human MS spinal cords contain increased levels of cyclooxygenase-2, CB 2 and P2X 7 receptors in affected regions compared to control spinal cords, with strong CB 2 immunoreactivity being found in microglia/macrophages of white matter areas, usually within or at the edge of plaque areas [64] . In addition, in brain plaques of active MS patients, CB 1 appears to be up-regulated in cortical neurons, oligodendrocytes, oligodendrocyte precursors, macrophages, and infiltrated T-lymphocytes, whereas CB 2 is over-expressed in T-lymphocytes, astrocytes, and perivascular and reactive microglia, and FAAH in neurons and hypertrophic astrocytes [65] . Finally, increased levels of anandamide were found in tissues from inflammatory lesions of patients with active or silent MS [66] . Therefore, also in humans the endocannabinoid system seems to be modulated during MS in CNS areas most involved in the disease and might play a role in counteracting the progress and symptoms of the disease. In agreement with this latter possibility, a genetic analysis very recently correlated the presence of an AAT repeat localized in the downstream region of the Cnr1 gene with primary progressive MS [67] , and clinical studies have shown that THC or cannabis extracts such as Sativex, which contains nearly equal amounts of THC and the other (non-pychotropic) cannabinoid, cannabidiol, can reduce pain, spasticity and incontinence in MS patients [68] [69] [70] [71] [72] .
AMYOTROPIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease that damages upper and lower motor neurons of the brain and spinal cord. The disorder causes muscle weakness and atrophy with speech and respiratory difficulties. The only currently established treatment for ALS is riluzole, a drug that reduces glutamate release from nerve terminals, although its therapeutic effects are minimal [73] . ALS is largely a sporadic disease, however, with around 10% of cases being familial, and of these 20% being due to mutations of the gene encoding in the Cu/Zn superoxide dismutase (SOD1) enzyme [74] . Potential therapeutic effects of selective stimulation of either CB 2 or CB 1 in ALS have been studied in the mutant SOD1 mouse model. Long-term elevation of endocannabinoid levels was observed in the lumbar section of spinal cords of SOD1(G93A) transgenic mice and suggested to be part of an endogenous defensive mechanism aimed at limiting neuronal cell damage [75, 76] . Furthermore, treatment of SOD1 (G93A) mice with a cannabinoid receptor agonist, or manipulation of endocannabinoid levels via genetic FAAH inactivation, significantly delayed disease progression [76] . These authors also reported that CB 1 deletion increased survival, suggesting that the elevated endocannabinoids do not act via CB 1 -mediated protection in this disorder. The hypothesis that other receptors, mainly CB 2 , could mediate the beneficial effects of the elevated endocannabinoid levels was also evaluated [77, 78] . AM1241, a selective CB 2 agonist, was effective at slowing signs of disease progression when administered after their onset in SOD1(G93A) mice. The mRNA, receptor binding and function of CB 2 , but not CB 1 was dramatically and selectively up-regulated in the spinal cords of G93A-SOD1 mice in a temporal pattern paralleling disease progression. A significant increase of CB 2 expression in post-mortem human spinal cord tissue of human subjects with ALS, localized in the dorsolateral white matter, was recently reported (64) .
PARKINSON'S DISEASE
The progressive degeneration of dopaminergic neurons of the substantia nigra pars compacta causes a severe dopaminergic denervation of the striatum leading to the most prevalent neurodegenerative disorder affecting the basal ganglia, known as Parkinson's disease (PD). The loss of dopamine input over striatal medium spiny neurons that, by controlling the information flow from the cortex, modulates motor activity and the whole circuit of the basal ganglia, explains the occurrence of pathological symptoms including bradykinesia, rigidity and tremor. The etiology of PD is still unclear, though environmental factors and genetic vulnerability have been considered [79, 80] , Current pharmacological treatment is based on the activation of dopamine (DA) receptors with levodopa, the biosynthetic precursor of DA. However, levodopa is useful only during the early and intermediate phases of disease and becomes less effective in the late phases when it also causes irreversible side effects such as dyskinesia.
During the early phase of PD, when nigral degeneration is not yet massive (less than 50% of neuronal cell death) and motor dysfunctions are still absent, CB 1 receptors are down-regulated. In fact, in three different transgenic mouse models of parkinsonism, PARK1, PARK2 and PARK6 encoding for -synuclein, parkin and PINK1 protein, respectively, CB 1 receptors are overactive at late and symptomatic phases but seem to be hypoactive selectively in the early and pre-symptomatic stages of the disorder [81] . This reduction, which might be used as an early biomarker for PD, could enhance neuron vulnerability to excitotoxic stimuli and participate in nigrostriatal degeneration. The late over-activity of CB 1 observed in this study is in agreement with the up-regulation of endocannabinoid signaling reported in patients or experimental animal models of PD (see below). In a more recent study, the early "CB 1 hypoactivity" phase of PD was further investigated in rats with 6-hydroxydopamine (6-OHDA)-induced nigrostriatal lesion [82] . CB 1 was expressed strongly in the substantia nigra pars reticulata, minimally overlapping with tyrosine hydroxylase immunoreactivity in the pars compacta. While there was little change in CB 1 expression following axonal lesion, expression of the receptor was significantly reduced following terminal lesion, and loss of receptor expression in the pars reticulata correlated significantly with the loss of striatal and nigral volume after terminal lesion. This indicated that this loss of CB 1 levels may have been due to 6-OHDA-induced, non-specific damage of striatonigral neurons, which are known to express CB 1 . The early loss of CB 1 in the 6-OHDA model of PD was also confirmed by a study carried out in vivo using positron emission tomography [83] . The relative binding of the positron emission tomographic CB 1 ligand [18F]MK-9470 was found decreased in the contralateral cerebellum and in the caudate-putamen bilaterally. Interestingly, the number of tyrosine hydroxylase-positive neurons in the substantia nigra was inversely correlated to CB 1 binding in the ipsilateral cerebellum, whereas the behavioral outcome was positively related to regional CB 1 binding in the contralateral somatosensory cortex.
As mentioned above, increased CB 1 binding and activation of GTP-binding proteins were observed in the basal ganglia of patients with PD [84] , and CB 1 mRNA levels were up-regulated in the caudate-putamen [85, 86] and substantia nigra [87] of rats with 6-OHDA-induced lesions in a late phase of the disorder. Furthermore, increased expression of CB 1 was also described in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated marmosets, another model of PD [84] , or in animals chronically treated with DA D2 antagonists [85] . Higher tissue contents of endocannabinoids have been observed also in PD. In particular, elevation of either anandamide levels in the cerebrospinal fluid of untreated PD patients [88] and in the striatum of 6-OHDA-treated rats [89] , or of 2-AG levels in the external layer of the globus pallidus of reserpine-treated rats [90] were reported. Moreover, these alterations in endocannabinoid signaling seem to be reversed by treatment with levodopa [84, 89, 91, 92] . Bearing in mind the hypokinetic effect observed in healthy animals following activation of CB 1 in the basal ganglia, these data suggest that late hyperactivity of the endocannabinoid system in PD might contribute to its symptoms and are concordant with the finding that CB 1 antagonists, per se or together with levodopa, can reduce bradykinesia in experimental models of this disorder in both rodents and non-human primates [90] [91] [92] [93] [94] [95] , possibly by counteracting impaired glutamatergic signalling in the striatum caused by nigro-striatal lesions [96] . On the other hand, other studies reported that CB 1 is down-regulated in reserpinized rats or PD patients [97, 98] , that endocannabinoid levels are reduced rather than increased in the striatum of 6-OHDA-treated rats [99] , and that treatment of PD patients with the CB 1 antagonist rimonabant did not lead to any amelioration of the symptoms [100] . Some controversy also exists as to whether endocannabinoids contribute to levodopa-induced dyskinesias, since some authors [92] , but not others [94] , found that CB 1 antagonists can counteract this symptom. There are reports that CB 1 agonists can also can ameliorate the dyskinesia, both in animal models [101, 102] and PD patients [103] . Interestingly, a FAAH inhibitor ameliorated levodopa-induced-dyskinesia in 6-OHDAtreated rats but only in the presence of a TRPV1 receptor antagonist, suggesting that pharmacologically elevated anandamide levels might act at both CB 1 and TRPV1 receptors, and that the latter might obstruct CB 1 -mediated inhibition of dyskinesias [102] .
The potential role of CB 2 receptors in PD is still controversial and seems to be dependent on the experimental animal model used. The selective CB 2 agonist, HU-308, slightly protected nigral neurons from 6-OHDA-induced DA depletion in rats [104] , whereas the neuroprotection provided by THC, cannabidiol and AM404 seems to be due to their antioxidant effect rather that to the activation of cannabinoid receptors [104, 105] . Recently, Price and co-workers reported that the non-selective cannabinoid agonist, WIN55, 212-2, protects mouse nigrostriatal neurons from MPTPinduced neurotoxicity and neuroinflammation [106] . Moreover, WIN55, 212-2 or the CB 2 -selective agonist, JWH-015, reduced MPTP-induced CB 2 -mediated microglial activation and these effects were reverted by a CB 2 antagonist, whereas genetic ablation of CB 2 exacerbated MPTP-induced systemic toxicity.
HUNTINGTON'S DISEASE
Huntington' s disease (HD) is an autosomal neurodegenerative disease, inherited dominantly, characterized by motor disturbances, dementia, psychiatric symptoms, and early death. HD is caused by a mutation (a CAG trinucleotide expansion) in exon 1 of the IT15 gene coding for huntingtin on chromosome 4 [107] . The expanded CAG repeat is translated into a polyglutamine (polyQ) expansion in the N-terminal region of huntingtin, which affects specific subpopulation of neurons in the striatum and cerebral cortex, accounting for motor abnormalities and cognitive disturbances, respectively.
Several studies have established a significant loss of CB 1 in post-mortem samples collected from patients at intermediate and advanced phases of HD [108] [109] [110] . This loss preceded neuronal cell loss due to this disorder, which predominantly affects mediumspiny GABAergic neurones, and occurred prior to impairment of other receptors. Similar events were described in different transgenic mouse models of HD [111] [112] [113] [114] [115] [116] , suggesting a correlation between reduced CB 1 expression and disease severity or progression. In particular, data obtained from different mouse models over-expressing mutated forms of HD, e.g. HD94, R6/1 and R6/2, suggested that the loss of CB 1 may be considered an event involved in the onset and/or in the early stage of disease rather than its consequence [111] [112] [113] [114] . Recently, a detailed analysis of CB 1 binding, protein, gene expression and endocannabinoid levels was performed just before the onset of the motor disturbance (12 weeks of age) in R6/1 transgenic mice. The authors reported a small but significant decrease of CB 1 ligand binding in the basal ganglia, and a 27% decrease in CB 1 mRNA in the striatum compared to wildtype mice, and suggested 12 weeks as the suitable time point to evaluate therapeutic therapies in R6/1 mice [117] . It is worthwhile noting that an enriched environment in R6/1 mice delays both CB 1 loss and onset of HD-like symptoms [118] . Importantly, in R6/2 mice, reduced CB 1 signalling results in reduced sensitivity of striatal GABA synapses to the negative control by CB 1 agonists, and subsequent enhanced GABA signalling [115] . This phenomenon appears already in the presymptomatic phase of this experimental model of HD, suggesting that the loss of CB 1 might be a compensatory mechanism aimed at counteracting, via subsequently disinhibited GABA release, the initial excitotoxic damage to striatal neurons [119] . On the other hand, the reduction of CB 1 was also suggested to increase the vulnerability of neurons toward different cytotoxic stimuli and contribute to the disease [120] .
Endocannabinoid levels are markedly reduced in animal models of HD. In particular, anandamide and 2-AG are decreased in the striatum of 3-nitropropionic acid-lesioned rats, an experimental model which reproduces the mitochondrial complex II deficiency observed during HD. CB 1 and endocannabinoid levels were unaltered in the cerebral cortex, an area not affected by the lesion [121] . In the same animal model, arvanil, UCM707 and AM404, inhibitors of endocannabinoid cellular re-uptake, reduced hyperkinesia and promoted recovery from neurochemical deficits [111, 122, 123, 55] . The hypokinetic effect observed with AM404, however, might be due mainly to the direct activation TRPV1 channels, as it was reverted by TRPV1 but not CB 1 , antagonists [122] . In another study, R6/2 mice at two different disease phases, pre-symptomatic (4.5 weeks) and symptomatic (10 weeks), were used as model to demonstrate a close relationship between disease symptoms and changes in endocannabinoid signalling in brain regions (striatum, cortex and hippocampus) involved in HD. In particular, a selective decrease of 2-AG levels in the cortex of presymptomatic R6/2 versus wild-type mice was observed. In symptomatic mice, both 2-AG and anandamide were decreased in the striatum, whereas opposite changes of anandamide (increase) and 2-AG (decrease) levels were found in the cortex [124] .
Recent data suggest that CB 2 protects striatal neurons from death in rats lesioned with malonate, which produces neuronal cell death through mechanisms that involve mainly apoptotic processes [125] . In particular, HU-308 reduced the magnitude of striatal lesions caused by malonate, and the effect was reverted by a selective CB 2 antagonist. Moreover, striatal CB 2 expression increased in response to neurodegeneration produced by a mitochondrial toxin and the magnitude of striatal lesion was increased following genetic CB 2 depletion [126] . A crucial role for CB 2 in the attenuation of microglial activation and prevention of neurodegeneration was also advanced by Palazuelos and coworkers [127] , who reported that expression of CB 2 increases in striatal microglia of R6/2 mice and its genetic ablation enhances microglial activation and exacerbates the symptoms of the disease.
CONCLUSIONS
From the literature reviewed in this article, the endocannabinod system emerges as a major player in neurodegenerative and neuroinflammatory disorders ( Table 1) . Both the expression of cannabinoid receptors and levels of endocannabinoids undergo time-and brain region-specific alterations during both early and late phases of the disorders. These changes, when they are not a direct consequence of neuronal cell loss, most likely represent early neuroadaptive mechanisms aimed at counteracting neurochemical inbalances in neurons (e.g. glutamate excitotoxicity) and at limiting the extent and duration of the accompanying inflammatory reactions in microglia and other glial cells. However, when timeand space-specificity of these mechanisms is lost, endocannabinoids might start contributing to the late progress and symptoms of the disorders. In some cases, early (as in the case of HD and PD) or late (as in the case of AD) impairment of endocannabinoid signalling might also participate in disease progression. The complexity of endocannabinoid function in neurodegenerative and neuroinflammatory disorders, therefore, opens the possibility for the therapeutic use of both "enhancers" and "blockers" of their action [22] . In the former case, the possible use of CB 1 agonists might be hindered by their psychotropic side effects which, however, seem to be significantly reduced in the case of THC when this compound is co-administered with cannabidiol, as in Sativex. Inhibitors of FAAH and monoacylglycerol lipase [17] , which would have the advantage of enhancing the action of endocannabinoids only at the site of their production, that is, in the brain areas directly affected by the disorder, might represent more specific strategies for treatment. In the case of FAAH inhibitors, the possible action of pharmacologically elevated levels of anandamide or of other endogenous FAAH substrates at other targets, such as TRPV1 channels, needs to be kept into account, for example by assessing the effect of dual FAAH/TRPV1 blockers, of which Narachidonoylserotonin is the most efficacious example to date [128] [129] [130] . Dual FAAH/monoacylglycerol lipase inhibitors, selective over other hydrolases, are being developed, but their use might be limited by their psychotropic effects, which are seemingly not too different from those of THC [131] . Selective CB 2 agonists might be efficacious in the treatment of neurodegenerative and neuroinflammatory disorders, although they might have a narrow therapeutic window. On the side of endocannabinoid "blockers", CB 1 and CB 2 antagonists have shown some promise in animal models of AD or PD and MS, respectively, but it is not clear yet whether they can be used efficaciously and safely in the clinic, especially after the report of psychiatric side effects with the former type of compounds (although so far only in obese subjects) [22] .
Indeed, only few clinical trials have been carried out so far with synthetic endocannabinoid-based drugs in neurodegenerative and neuroinflammatory disorders, mostly limited to: phase I trials with CB1 agonists and antagonists in PD, a so far unpublished study with a CB1 antagonist in AD, and several more advanced studies with THC or its analogue nabilone in MS. By contrast, Sativex has been investigated in several phase II and III clinical trials, and not just limited to MS. All these studies, however, have only evaluated the possible symptomatic and/or palliative use of these compounds or Cannabis extracts. Therefore, more placebo-controlled, doubleblind studies in patients with these disorders are now needed to provide a more definitive answer to the question of whether or not the endocannabinoid system can be exploited for the development of new therapies against the progress, and not just the symptoms, of neurodegenerative and neuroinflammatory disorders. Although discrepancies exist in the literature, depending on the experimental models used, the data summarised reflect the overall outcome of the studies. Abbreviations: CREAE, chronic-relapsing experimental allergic encephalomyelitis; EAE, experimental allergic encephalomyelitis; LID, levodopa-induced dyskinesia; MS, multiple sclerosis; TMEV-IDD, Theiler murine encephalomyelitis virus-induced demyelinating disease; SOD, superoxide dismutase; TRPV1, transient receptor potential of vanilloid type-1 channel.
6-OHDA = 6-Hydroxydopamine 
